Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?

Key Takeaways Lilly's obesity portfolio features late-stage candidates orforglipron and retatrutide.Orforglipron, a daily oral GLP-1 pill, could offer a convenient option versus injectables.Retatrutide may enable deeper and faster weight loss, with key phase III data due from 2025-2027.Eli Lilly and Company (LLY) is one of the two companies that dominate the booming diabetes and obesity space, driven by its successful GLP-1 therapies — Mounjaro for diabetes and Zepbound for weight loss, both comprising the ...